


PHARMACEUTICAL 2019

AYTU BIOPHARMA INC Rank 203 of 371







PHARMACEUTICAL 2019

AYTU BIOPHARMA INC Rank 203 of 371



The relative strengths and weaknesses of AYTU BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AYTU BIOPHARMA INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 292% points. The greatest weakness of AYTU BIOPHARMA INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 264% points.

The company's Economic Capital Ratio, given in the ranking table, is -185%, being 146% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	9,470
Cost of Goods Sold	2,051
Intangible Assets	246
Liabilities, Current	3,395
Liabilities, Non-Current	0
Other Assets	11,125
Other Compr. Net Income	0
Other Expenses	3,410
Other Liabilities	4,241
Other Net Income	9,512
Property and Equipment	219
Research and Development	168
Revenues	3,660
Selling, General and Administrative Expense	17,732

Output Variable	Value in 1000 USD
Assets	21,060
Liabilities	7,636
Expenses	23,360
Stockholders Equity	13,425
Net Income	-10,188
Comprehensive Net Income	-10,188
Economic Capital Ratio	-185%